Navigation Links
DURECT Corporation Secures $50 Million Committed Equity Financing Facility
Date:7/1/2010

CUPERTINO, Calif., July 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has secured a committed equity financing facility under which it may sell up to $50 million of its registered common stock to Azimuth Opportunity Ltd. for a term of 24 months.  DURECT is not obligated to utilize any of the $50 million facility.  DURECT did not pay a commitment fee or issue any warrants to secure this facility.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

DURECT will determine, at its sole discretion, the timing, the dollar amount, and the floor price per share of any drawdown under this facility, subject to certain defined limitations.  Any shares sold under this facility will be sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 11, 2009, as amended.

"DURECT has been able to maintain a strong financial position and modest cash burn rate while building our late stage pipeline of product candidates through our licensing strategy," stated James E. Brown, President and CEO of DURECT Corporation.  "Establishing this equity line of credit gives us greater flexibility to access additional capital with low transaction costs if we deem it appropriate over the next two years."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding any future sale of shares of DURECT's common stock to Azimuth Opportunity Ltd., the price for such sales and DURECT's capital needs in the future are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.  Potential risks and uncertainties include, but are not limited to volatility in the price of our common stock, our ability to successfully complete clinical trials and other development activities in a timely manner and secure regulatory approval for our product candidates, manufacture, commercialize and obtain marketplace acceptance of our product candidates, whether we receive milestone and royalty payments based on activities of our collaborators, our ability to maintain our corporate collaborations with third parties and enter into new collaborations, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on May 10, 2010 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
(Date:2/10/2016)... , Feb. 10, 2016 ... synergistic confluence of various technologies that results ... previously unavailable. These opportunities create a cyclical ... in turn, drives the development of new ... is characterized by technology convergences, which are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... ... 2016 , ... Pediatric therapists are challenged to use evidence ... the Goal Attainment Scale (GAS) captures 20% more change in outcomes than other ... the Goal Attainment Scale, Education Resources Inc. is offering a course focused on ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine ... provide a solution that ensures the integrity of biological samples while operating at ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans ... start of Medicare Part D a decade ago, according to The Senior Citizens ... adults on how they are coping with rapidly rising costs. “The implications are ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury is ... may be one of many possible sources: sports, car accidents, falls, work accidents, ... Mastering Rehab Solutions for the Complexities of Concussions is designed for ...
Breaking Medicine News(10 mins):